Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Double Blind Phase III Trial Comparative Clinical Safety, Efficacy and Immunogenicity of Adalimumab (Manufactured by Mabscale, LLC) to Humira®.

NCT06005532 is registered in ClinicalTrials.gov with Mabscale, LLC as lead sponsor.

NCT NCT06005532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06005532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Double Blind Phase III Trial Comparative Clinical Safety, Efficacy and Immunogenicity of Adalimumab (Manufactured by Mabscale, LLC) to Humira®.
Lead sponsor
Mabscale, LLC
Phase
Phase 3
Overall status
Unknown status
Start date
October 2, 2023
Completion date
December 31, 2025
Enrollment
494 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis